Risk of adverse coronavirus disease 2019 outcomes for people living with HIV
- PMID: 33587448
- PMCID: PMC7924978
- DOI: 10.1097/QAD.0000000000002836
Risk of adverse coronavirus disease 2019 outcomes for people living with HIV
Abstract
Objective: To assess whether people living with HIV (PLWH) are at increased risk of coronavirus disease 2019 (COVID-19) mortality or adverse outcomes, and whether antiretroviral therapy (ART) influences this risk.
Design: Rapid review with meta-analysis and narrative synthesis.
Methods: We searched databases including Embase, Medline, medRxiv and Google Scholar up to 26 August 2020 for studies describing COVID-19 outcomes in PLWH and conducted a meta-analysis of higher quality studies.
Results: We identified 1908 studies and included 19 in the review. In a meta-analysis of five studies, PLWH had a higher risk of COVID-19 mortality [hazard ratio 1.95, 95% confidence interval (CI): 1.62-2.34] compared with people without HIV. Risk of death remained elevated for PLWH in a subgroup analysis of hospitalized cohorts (hazard ratio 1.60, 95% CI: 1.12-2.27) and studies of PLWH across all settings (hazard ratio 2.08, 95% CI: 1.69-2.56). Eight other studies assessed the association between HIV and COVID-19 outcomes, but provided inconclusive, lower quality evidence due to potential confounding and selection bias. There were insufficient data on the effect of CD4+ T-cell count and HIV viral load on COVID-19 outcomes. Eleven studies reported COVID-19 outcomes by ART-regimen. In the two largest studies, tenofovir disoproxil fumarate-based regimens were associated with a lower risk of adverse COVID-19 outcomes, although these analyses are susceptible to confounding by co-morbidities.
Conclusion: Emerging evidence suggests a moderately increased risk of COVID-19 mortality among PLWH. Further investigation into the relationship between COVID-19 outcomes and CD4+ T-cell count, HIV viral load, ART and the use of tenofovir disoproxil fumarate is warranted.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
There are no conflicts of interest.
Figures
Comment in
-
An updated meta-analysis on the association between HIV infection and COVID-19 mortality.AIDS. 2021 Sep 1;35(11):1875-1878. doi: 10.1097/QAD.0000000000002968. AIDS. 2021. PMID: 34397487 No abstract available.
Similar articles
-
Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV.Viruses. 2023 May 9;15(5):1127. doi: 10.3390/v15051127. Viruses. 2023. PMID: 37243213 Free PMC article.
-
Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV.AIDS. 2022 Oct 1;36(12):1689-1696. doi: 10.1097/QAD.0000000000003314. Epub 2022 Jul 15. AIDS. 2022. PMID: 35848570 Free PMC article.
-
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.Lancet Infect Dis. 2016 Jan;16(1):43-52. doi: 10.1016/S1473-3099(15)00348-5. Epub 2015 Nov 2. Lancet Infect Dis. 2016. PMID: 26538525 Clinical Trial.
-
Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.Int J Infect Dis. 2020 Apr;93:108-117. doi: 10.1016/j.ijid.2020.01.035. Epub 2020 Jan 25. Int J Infect Dis. 2020. PMID: 31988012 Review.
-
Clinical outcomes and immunological response to SARS-CoV-2 infection among people living with HIV.Exp Biol Med (Maywood). 2024 Apr 2;249:10059. doi: 10.3389/ebm.2024.10059. eCollection 2024. Exp Biol Med (Maywood). 2024. PMID: 38628843 Free PMC article. Review.
Cited by
-
COVID-19 vaccination willingness among people living with HIV in Shijiazhuang, China: a cross-sectional survey.Front Med (Lausanne). 2024 Jan 17;11:1322440. doi: 10.3389/fmed.2024.1322440. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38314204 Free PMC article.
-
Prevalence and Mortality due to COVID-19 in HIV Co-Infected Population: A Systematic Review and Meta-Analysis.Infect Dis Ther. 2021 Sep;10(3):1267-1285. doi: 10.1007/s40121-021-00447-1. Epub 2021 May 3. Infect Dis Ther. 2021. PMID: 33939121 Free PMC article.
-
COVID-19 outcomes in people living with HIV: Peering through the waves.Clinics (Sao Paulo). 2023 May 25;78:100223. doi: 10.1016/j.clinsp.2023.100223. eCollection 2023. Clinics (Sao Paulo). 2023. PMID: 37331214 Free PMC article.
-
Effect of Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Booster on Human Immunodeficiency Virus Reservoirs and Immune Markers.Open Forum Infect Dis. 2022 Oct 17;9(11):ofac544. doi: 10.1093/ofid/ofac544. eCollection 2022 Nov. Open Forum Infect Dis. 2022. PMID: 36345429 Free PMC article.
-
Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection.Pharmaceuticals (Basel). 2021 May 11;14(5):454. doi: 10.3390/ph14050454. Pharmaceuticals (Basel). 2021. PMID: 34064831 Free PMC article. Review.
References
-
- World Health Organization (WHO). Weekly operational update on COVID-19, 21 August 2020. 2020; Geneva: World Health Organization (WHO), Available at: https://www.who.int/publications/m/item/weekly-update-on-covid-19---21-a.... [Accessed 18 January 2021].
-
- World Health Organization. HIV/AIDS fact sheet. 2020; Geneva: World Health Organization, Available at: https://www.who.int/news-room/fact-sheets/detail/hiv-aids. [Accessed 18 January 2021].
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials